Jonathan Beers, DO
Internal Medicine · Rolla, MONPI 1477783686
Payments from drug & device makers
Across 188 payments — averaging $14.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$360
- Amgen$338
- GSK$299
- Novo Nordisk$254
- Pfizer$240
- AbbVie$181
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,65999%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $360 |
| Amgen | 21 | $338 |
| GSK | 34 | $299 |
| Novo Nordisk | 21 | $254 |
| Pfizer | 18 | $240 |
| AbbVie(2 entities) | 9 | $181 |
| Johnson & Johnson | 8 | $120 |
| Novartis | 8 | $108 |
| Abbott | 4 | $80 |
| Grifols USA, LLC | 5 | $76 |
| Boehringer Ingelheim | 5 | $76 |
| Otsuka America Pharmaceutical, Inc. | 4 | $61 |
| Eisai Inc. | 4 | $58 |
| Bayer | 4 | $58 |
| Lilly USA, LLC | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $42 |
| Advanced Respiratory, Inc | 2 | $38 |
| Sanofi-aventis U.S. LLC | 3 | $36 |
| Philips North America LLC | 2 | $35 |
| Resmed Corp | 2 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $26 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Apria Healthcare LLC | 1 | $23 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Dexcom, Inc. | 1 | $12 |
| Mylan Specialty L.p. | 1 | $11 |
How this compares
$2,674 in reported general payments places this provider in the 80th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 551 | $173,568 |
| XareltoRivaroxaban | 187 | $56,011 |
| Invega SustennaPaliperidone Palmitate | 13 | $33,559 |
| OzempicSemaglutide | 19 | $20,562 |
| JardianceEmpagliflozin | 61 | $19,814 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $19,507 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $16,302 |
| JanuviaSitagliptin Phosphate | 52 | $15,856 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 23 | $13,803 |
| MyrbetriqMirabegron | 50 | $13,302 |
| RexultiBrexpiprazole | 19 | $13,174 |
| EntrestoSacubitril/Valsartan | 16 | $10,445 |
| SantylCollagenase Clostridium Hist. | 12 | $7,195 |
| Potassium Chloride | 383 | $6,948 |
| LinzessLinaclotide | 11 | $6,810 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $240 | $173,568551 claims |
| Johnson & JohnsonXarelto, Invega Sustenna | $120 | $89,570200 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $299 | $31,40658 claims |
| Novo NordiskOzempic | $254 | $20,56219 claims |
| Boehringer IngelheimJardiance | $76 | $19,81461 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $61 | $13,17419 claims |
| NovartisEntresto | $108 | $10,44516 claims |
| AbbVieLinzess | $181 | $6,81011 claims |
| Sanofi-aventis U.S. LLCLantus | $36 | $6,73091 claims |
| AstraZenecaBrilinta | $360 | $4,89217 claims |
| Lilly USA, LLCHumalog | $46 | $3,12741 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Rolla
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.